US5654451B1
(en)
|
1993-01-14 |
2000-02-22 |
Magainin Pharma |
Amino acids and peptides having modified c-terminals and modified n-terminals
|
JPH08505854A
(ja)
|
1993-01-14 |
1996-06-25 |
マガイニン ファーマシューティカルズ,インク. |
修飾された末端を有するアミノ酸及びペプチド
|
EP1532118A2
(en)
|
2002-07-05 |
2005-05-25 |
Axxima Pharmaceuticals Aktiengesellschaft |
Imidazole compounds for the treatment of hepatitis c virus infections
|
US7183302B2
(en)
|
2002-08-12 |
2007-02-27 |
Bristol-Myers Squibb Company |
Iminothiazolidinones as inhibitors of HCV replication
|
DE102004036971B4
(de)
|
2004-07-30 |
2009-07-30 |
Advanced Micro Devices, Inc., Sunnyvale |
Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
|
WO2006022442A1
(ja)
|
2004-08-24 |
2006-03-02 |
Santen Pharmaceutical Co., Ltd. |
ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
|
GB2438802A
(en)
|
2005-02-28 |
2007-12-05 |
Univ Rockefeller |
Structure of the hepatitis C virus NS5A protein
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
BRPI0615934A2
(pt)
|
2005-09-16 |
2011-05-31 |
Arrow Therapeutics Ltd |
composto ou um sal farmaceuticamente aceitável do mesmo, uso de um derivado de bifenila, composição farmacêutica, e, produto
|
WO2007058384A1
(en)
|
2005-11-17 |
2007-05-24 |
Osaka University |
Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
|
US7910595B2
(en)
|
2005-12-21 |
2011-03-22 |
Abbott Laboratories |
Anti-viral compounds
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
SG133452A1
(en)
|
2005-12-30 |
2007-07-30 |
Novartis Ag |
Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
|
CA2653924A1
(en)
|
2006-05-30 |
2007-12-06 |
Arrow Therapeutics Limited |
Biphenyl derivatives and their use in treating hepatitis c
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8303944B2
(en)
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100158862A1
(en)
|
2006-08-11 |
2010-06-24 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CN101558059B
(zh)
*
|
2006-08-11 |
2014-12-03 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7745636B2
(en)
|
2006-08-11 |
2010-06-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2010510245A
(ja)
|
2006-11-21 |
2010-04-02 |
スミスクライン ビーチャム コーポレーション |
抗ウイルス化合物
|
WO2008133753A2
(en)
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
MX2010008699A
(es)
|
2008-02-12 |
2010-08-30 |
Bristol Myers Squibb Co |
Derivados heterociclicos como inhibidores de virus de la hepatitis c.
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010062821A1
(en)
|
2008-11-28 |
2010-06-03 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
EP2373172B1
(en)
|
2008-12-03 |
2013-07-17 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2010065681A1
(en)
|
2008-12-03 |
2010-06-10 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
ES2567047T3
(es)
|
2008-12-23 |
2016-04-19 |
Abbvie Inc. |
Derivados de pirimidina anti-virales
|
WO2010091413A1
(en)
|
2009-02-09 |
2010-08-12 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
WO2010094977A1
(en)
|
2009-02-23 |
2010-08-26 |
Arrow Therapeutics Limited |
Novel biphenyl compounds useful for the treatment of hepatitis c
|
EP2398474A4
(en)
|
2009-02-23 |
2012-12-05 |
Presidio Pharmaceuticals Inc |
HCV NS5A SHEMMER
|
BRPI1007836A2
(pt)
|
2009-02-27 |
2015-09-01 |
Enanta Phamaceuticals Inc |
Inibidores do vírus c da hepatite
|
KR20110131312A
(ko)
|
2009-03-27 |
2011-12-06 |
프레시디오 파마슈티칼스, 인코포레이티드 |
융합된 고리 c형 간염 억제제
|
CN102427729B
(zh)
|
2009-03-27 |
2014-09-03 |
默沙东公司 |
丙型肝炎病毒复制的抑制剂
|
US8709999B2
(en)
|
2009-03-27 |
2014-04-29 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
US20110237636A1
(en)
|
2009-03-30 |
2011-09-29 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI476190B
(zh)
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
TW201038559A
(en)
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
SG175144A1
(en)
|
2009-04-15 |
2011-11-28 |
Abbott Lab |
Anti-viral compounds
|
US20120115918A1
(en)
|
2009-04-15 |
2012-05-10 |
Abbott Laboratories |
Anti-Viral Compounds
|
JP2012524761A
(ja)
|
2009-04-24 |
2012-10-18 |
テイボテク・フアーマシユーチカルズ |
ジアリールエーテル類
|
US9139569B2
(en)
|
2009-05-12 |
2015-09-22 |
Merck Sharp & Dohme Corp. |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
NZ596444A
(en)
|
2009-05-13 |
2014-01-31 |
Gilead Sciences Inc |
Antiviral compounds
|
EP2435421A1
(en)
|
2009-05-29 |
2012-04-04 |
Schering Corporation |
Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
|
US8138215B2
(en)
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8211928B2
(en)
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010138791A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
RS53856B1
(en)
|
2009-06-11 |
2015-08-31 |
Abbvie Bahamas Ltd. |
HETEROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
|
US9394279B2
(en)
|
2009-06-11 |
2016-07-19 |
Abbvie Inc. |
Anti-viral compounds
|
WO2010148006A1
(en)
|
2009-06-16 |
2010-12-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
US8354419B2
(en)
|
2009-07-16 |
2013-01-15 |
Vertex Pharmaceuticals Incorporated |
Benzimidazole analogues for the treatment or prevention of flavivirus infections
|
CN102471324B
(zh)
|
2009-08-07 |
2014-12-17 |
泰博特克药品公司 |
作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
|
CA2768637A1
(en)
|
2009-08-07 |
2011-02-10 |
Tibotec Pharmaceuticals |
Phenyl ethynyl derivatives as hepatitis c virus inhibitors
|
WO2011026920A1
(en)
|
2009-09-03 |
2011-03-10 |
Tibotec Pharmaceuticals |
Bis-benzimidazole derivatives
|
MX2012002759A
(es)
|
2009-09-04 |
2012-04-30 |
Glaxosmithkline Llc |
Compuestos quimicos.
|
EP2475256A4
(en)
|
2009-09-11 |
2013-06-05 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
EP2475254A4
(en)
|
2009-09-11 |
2013-05-22 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011050146A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxosmithkline Llc |
Chemical compounds
|
UA108211C2
(uk)
|
2009-11-04 |
2015-04-10 |
Янссен Рід Айрленд |
Бензімідазолімідазольні похідні
|
US20110269956A1
(en)
*
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20120276047A1
(en)
|
2009-11-25 |
2012-11-01 |
Rosenblum Stuart B |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
MY179840A
(en)
|
2009-12-04 |
2020-11-18 |
National Health Res Inst |
Proline derivatives
|
EP2512480A4
(en)
|
2009-12-14 |
2013-05-15 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
US8377980B2
(en)
*
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2011075607A1
(en)
|
2009-12-18 |
2011-06-23 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
CN102822175A
(zh)
|
2009-12-18 |
2012-12-12 |
埃迪尼克斯医药公司 |
5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
|
US20130156731A1
(en)
|
2009-12-22 |
2013-06-20 |
Kevin X. Chen |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
|
KR20120130173A
(ko)
|
2009-12-24 |
2012-11-29 |
버텍스 파마슈티칼스 인코포레이티드 |
플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
|
US8362020B2
(en)
*
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2011091446A1
(en)
|
2010-01-22 |
2011-07-28 |
Glaxosmithkline Llc |
Chemical compounds
|
CN102843909A
(zh)
|
2010-01-25 |
2012-12-26 |
埃南塔制药公司 |
丙型肝炎病毒抑制剂
|
EP2528926A4
(en)
|
2010-01-28 |
2013-06-19 |
Boehringer Ingelheim Int |
HEPATITIS C INHIBITOR COMPOUNDS
|
US8178531B2
(en)
|
2010-02-23 |
2012-05-15 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
US8623814B2
(en)
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
JP2013521279A
(ja)
|
2010-03-04 |
2013-06-10 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Hcv複製の阻害剤としての医薬併用剤
|
BR112012022125A2
(pt)
|
2010-03-09 |
2016-11-01 |
Merck Sharp & Dhme Corp |
composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
|
WO2011119870A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
JP2013522375A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
TW201141857A
(en)
|
2010-03-24 |
2011-12-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
WO2011127350A1
(en)
|
2010-04-09 |
2011-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2011146401A1
(en)
|
2010-05-17 |
2011-11-24 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
CA2800509A1
(en)
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
CA2800530A1
(en)
|
2010-05-28 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2011153396A1
(en)
*
|
2010-06-04 |
2011-12-08 |
Enanta Pharmaceuticals, Inc |
Hepatitis c virus inhibitors
|
US20130310427A1
(en)
|
2010-06-09 |
2013-11-21 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a protein
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
WO2012003642A1
(en)
|
2010-07-09 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and use thereof for treating viral diseases
|
CA2805440A1
(en)
|
2010-07-26 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
WO2012013643A1
(en)
|
2010-07-26 |
2012-02-02 |
Tibotec Pharmaceuticals |
Hetero-bicyclic derivatives as hcv inhibitors
|
WO2012018325A1
(en)
|
2010-08-04 |
2012-02-09 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US20120196794A1
(en)
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
US20120195857A1
(en)
|
2010-08-12 |
2012-08-02 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8697704B2
(en)
|
2010-08-12 |
2014-04-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
WO2012027712A2
(en)
|
2010-08-26 |
2012-03-01 |
Rfs Pharma, Llc |
Potent and selective inhibitors of hepatitis c virus
|
WO2012040389A2
(en)
|
2010-09-22 |
2012-03-29 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic hcv inhibitors
|
EP2621932A4
(en)
|
2010-09-29 |
2014-03-26 |
Merck Sharp & Dohme |
TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
WO2012040924A1
(en)
|
2010-09-29 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
|
US9254292B2
(en)
|
2010-09-29 |
2016-02-09 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
MX2013003631A
(es)
|
2010-09-29 |
2013-10-01 |
Merck Sharp & Dohme |
Derivados de indol tetraciclicos y sus métodos para el tratamiento de enfermedades virales.
|
WO2012040923A1
(en)
|
2010-09-29 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
|
WO2012050918A2
(en)
|
2010-09-29 |
2012-04-19 |
Presidio Pharmaceutical, Inc. |
Tricyclic fused ring inhibitors of hepatitis c
|
KR20130120469A
(ko)
|
2010-09-29 |
2013-11-04 |
머크 샤프 앤드 돔 코포레이션 |
폴리시클릭 헤테로사이클 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
|
WO2012048421A1
(en)
|
2010-10-14 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
CA2814534A1
(en)
|
2010-11-04 |
2012-05-10 |
Theravance, Inc. |
Novel inhibitors of hepatitis c virus
|
CA3095528C
(en)
|
2010-11-17 |
2023-07-18 |
Gilead Pharmasset Llc |
Antiviral compounds
|
RU2452735C1
(ru)
|
2010-11-30 |
2012-06-10 |
Александр Васильевич Иващенко |
Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
|
EP2651920A4
(en)
|
2010-12-15 |
2014-12-17 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
EP2651927A4
(en)
|
2010-12-15 |
2014-06-04 |
Abbvie Inc |
ANTIVIRAL CONNECTIONS
|
WO2012083061A2
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
WO2012083043A1
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
EP2651926A4
(en)
|
2010-12-15 |
2014-07-09 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
US20140343286A1
(en)
|
2010-12-15 |
2014-11-20 |
Allan C. Krueger |
Anti-viral compounds
|
EP2651885A1
(en)
|
2010-12-16 |
2013-10-23 |
Abbvie Inc. |
Anti-viral compounds
|
WO2012087976A2
(en)
|
2010-12-21 |
2012-06-28 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
WO2012122716A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9546160B2
(en)
|
2011-05-12 |
2017-01-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012162580A2
(en)
|
2011-05-26 |
2012-11-29 |
Abbvie Inc |
Anti-viral compounds
|
WO2012162578A2
(en)
|
2011-05-26 |
2012-11-29 |
Abbvie Inc. |
Anti-viral compounds
|
SG194681A1
(en)
|
2011-05-27 |
2013-12-30 |
Achillion Pharmaceuticals Inc |
Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
|
US20120328565A1
(en)
|
2011-06-24 |
2012-12-27 |
Brinkman John A |
Antiviral compounds
|
EP2730572B1
(en)
|
2011-07-09 |
2015-09-16 |
Sunshine Lake Pharma Co., Ltd. |
Spiro compounds as hepatitis c virus inhibitors
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|